Table 3 Changes in BMLs and clinical symptoms as a response to weight loss
Per protocol analyses | Per protocol analyses | |||
|---|---|---|---|---|
Patients with baseline BML score ≥ 0 | Patients with baseline BML score > 0 | |||
N = 169 | N = 139 | |||
Weight loss | Weight loss | Weight loss | Weight loss | |
< 10 % | ≥ 10 % | < 10 % | ≥ 10 % | |
Change in the sum of all BML scores | ||||
Responders | N = 5 (15 %) | N = 34 (25 %) | N = 5 (20 %) | N = 34 (30 %) |
Non-responders | N = 29 (85 %) | N = 101 (75 %) | N = 20 (80 %) | N = 80 (70 %) |
Change in the maximum BML score | ||||
Responders | N = 5 (15 %) | N = 23 (17 %) | N = 5 (20 %) | N = 23 (20 %) |
Non-responders | N = 29 (85 %) | N = 112 (83 %) | N = 20 (80 %) | N = 91 (80 %) |
OMERACT-OARSI response | ||||
Responders | N = 16 (47 %) | N = 103 (76 %) | N = 13 (52 %) | N = 87 (76 %) |
Non-responders | N = 18 (53 %) | N = 32 (24 %) | N = 12 (48 %) | N = 27 (32 %) |